Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OraPharma Inc.

Division of Bausch Health Companies Inc.
www.orapharma.com

Latest From OraPharma Inc.

Valeant OTC Strategy Leverages “Relationships With Doctors”

The Canadian specialty pharma firm plans to continue bolt-on acquisitions in 2014, including more OTC products that are doctor recommended, executives say.

Consumer BioPharmaceutical

Valeant OTC Strategy Leverages “Relationships With Doctors”

The Canadian specialty pharma firm plans to continue bolt-on acquisitions in 2014, including more OTC products that are doctor recommended, executives say.

Consumer BioPharmaceutical

Acquisitive Valeant Sheds Staff As It Closes Bausch & Lomb Deal

The fast-growing, Canadian specialty pharma will shed thousands of jobs as it absorbs Bausch & Lomb, as part of an endeavor to save $800 million. CEO Mike Pearson’s note to employees describes a new organizational philosophy, with restructured management and business units.

BioPharmaceutical United States

Biopharma Quarterly Deal Statistics, Q2 2012

Follow-on public offerings continued to dominate, with 19 transactions making up almost half of Q2’s $2.7 billion financing volume. M&A dollars, up nearly four times that of Q1, totaled $34.7 billion, for 28 completed transactions, seven of which topped the billion dollar mark. In alliances, the Q2 potential deal value – also largely increased over the previous quarter’s – marked possibly the highest amount ever seen along with maybe the most expensive deal ever: Walgreen $6.6 billion agreement to purchase a minority equity share in Alliance Boots, bringing in over half of Q2’s value.

BioPharmaceutical Deals
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
    • OTC, Consumer
  • Therapeutic Areas
  • Dental & Oral Products
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Bausch Health Companies Inc.
  • Senior Management
  • Michael D Kishbauch, Pres. & CEO
    Jim Ratigan, EVP, CFO
    Ron Lawter, EVP, CSO
    Russell Secter, VP, Sales & Mktg.
  • Contact Info
  • OraPharma Inc.
    Phone: (215) 956-2200
    5 Walnut Grove Dr., Ste. 300
    Horsham, PA 19044
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register